skip to main content
Idioma:
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

POS1215 FLARES AFTER COVID-19 INFECTION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM THE COVAD STUDY

Ali, S. S. ; Ravichandran, N. ; Sen, P. ; Day, J. ; Joshi, M. ; Saha, S. ; Aggarwal, R. ; Agarwal, V. ; Chinoy, H. ; Distler, O. ; Vinicio Caballero, C. ; Toro Gutierrez, C. E. ; Dzifa, D. ; Makol, A. ; Tan, A. L. ; Katsuyuki Shinjo, S. ; Gupta, L.

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.941-942 [Periódico revisado por pares]

London: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
  • Título:
    POS1215 FLARES AFTER COVID-19 INFECTION IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: RESULTS FROM THE COVAD STUDY
  • Autor: Ali, S. S. ; Ravichandran, N. ; Sen, P. ; Day, J. ; Joshi, M. ; Saha, S. ; Aggarwal, R. ; Agarwal, V. ; Chinoy, H. ; Distler, O. ; Vinicio Caballero, C. ; Toro Gutierrez, C. E. ; Dzifa, D. ; Makol, A. ; Tan, A. L. ; Katsuyuki Shinjo, S. ; Gupta, L.
  • Assuntos: Age ; Arthralgia ; Asthma ; Autoimmune diseases ; Comorbidity ; COVID-19 ; COVID-19 vaccines ; Dermatomyositis ; Disease ; Immunosuppression ; Inflammatory diseases ; Medical research ; Musculoskeletal diseases ; Myalgia ; Myositis ; Pandemics ; Patients ; Research funding ; Rheumatology ; Risk factors ; Scleroderma ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Statistics ; Surveys ; Systemic sclerosis
  • É parte de: Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.941-942
  • Descrição: Background Viral infections are known triggers of disease flares in idiopathic inflammatory myopathies (IIMs). Reports of post-COVID-19 flares of IIMs have raised suspicion of a possible role of SARS-COV-2 in their onset [1,2]. However, despite rising flare rates in this vulnerable patient group during the pandemic, the risk factors for post-COVID-19 IIMs flares remain unknown [3,4]. Objectives Disease flares among patients with idiopathic inflammatory myopathies (IIMs) can lead to significant disability, though are poorly explored in the post-COVID-19 period. We analysed risk factors for post-COVID-19 flares in a global sample of IIM patients in a subset analysis as part of the ongoing COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods A cross-sectional patient self-reporting survey was circulated by the international COVAD study group (157 collaborators, 106 countries) to patients with autoimmune diseases and healthy controls from February-June 2022. Data was collected on demographics, autoimmune disease details, treatment history, comorbidities, COVID-19 history and course and COVID-19 vaccination details. Patients with IIMs who flared post COVID-19 were compared to those who did not using the χ 2 test, factors found significant in univariate analysis and deemed clinically important, underwent multivariable analysis (binary logistic regression using the Enter method) with adjustment for age, gender, ethnicity, vaccine type, immunosuppression, autoimmune and non-autoimmune comorbidities, COVID-19 antibody status, and clinical symptoms of COVID-19. Statistical analyses were performed using IBM SPSS version 28.0, with statistical significance considered at p<0.05. Results 15,165 respondents completed the survey of whom 1,169 contracted COVID-19. Of these, 207 had IIMs [median (IQR) age 57.0 (47.0-67.0), 71% female, 74.4% Caucasian]. We noted with concern that nearly a third of patients with IIMs (63/207, 30.4%) reported experiencing a flare. A past medical history significant for Asthma, (34.9% vs 6.9%, multivariable OR: 7.1; 95%CI: 3.1-16.4, p<0.001) and specific clinical symptoms during COVID-19 including joint pains (multivariable OR: 6.05; 95%CI: 1.60-22.9, p=0.008), and difficulty in breathing (multivariable OR: 3.43; 95%CI: 1.09-10.8, p=0.036) were found to confer conferred a higher risk of flares (Table 1). Table 1 Patient Reported Flares following COVID-19 infection among IIM patients Total IIMs (n=207) IIMs with flare after COVID-19 (n=63) IIMs without flare after COVID-19 (n=144) OR (95%CI) P Age (median, IQR) years 57.0 (47.0-67.0) 53.0 (47.0-62.0) 59.0 (47.0-69.0) - 0.024 Gender Male Female 60 (29.0) 147 (71.0) 7 (11.1) 56 (88.9) 53 (36.8) 91 (63.2) 0.2 (0.09-0.5) < 0.001 Comorbidities Asthma ILD 32 (15.5) 31 (15.0) 22 (34.9) 11 (17.5) 10 (6.9) 20 (13.9) 7.1 (3.1-16.4) 1.3 (0.5-2.9) <0.001 00.508 Clinical features in previous COVID-19 infection Fatigue Myalgia Arthralgia Difficulty in breathing 134 (64.7) 94 (45.4) 56 (27.1) 41 (19.8) 52 (82.5) 44 (69.8) 36 (57.1) 27 (42.9) 82 (56.9) 50 (34.7) 20 (13.9) 14 (9.7) 3.5 (1.7-7.4) 4.3 (2.3-8.2) 8.2 (4.1-16.4) 6.9 (3.3-14.6) <0.001 <0.001 <0.001 <0.001 Conclusion We observed a high frequency of patients with IIM experiencing post-COVID-19 disease flares. A past history of Asthma and those with certain acute COVID-19 symptoms were at higher risk. References [1]Saud A, Naveen R, Aggarwal R, Gupta L. COVID-19 and Myositis: What We Know So Far. Curr Rheumatol Rep 2021;23:63. [2]Gokhale Y, Patankar A, Holla U, Shilke M, Kalekar L, Karnik ND, et al. Dermatomyositis during COVID-19 Pandemic (A Case Series): Is there a Cause Effect Relationship? J Assoc Physicians India 2020;68:20–4. [3]Gupta L, Lilleker JB, Agarwal V, Chinoy H, Aggarwal R. COVID-19 and myositis - unique challenges for patients. Rheumatology (Oxford) 2021;60:907–10. [4]Naveen R, Sundaram TG, Agarwal V, Gupta L. Teleconsultation experience with the idiopathic inflammatory myopathies: a prospective observational cohort study during the COVID-19 pandemic. Rheumatol Int 2021;41:67–76. Acknowledgements: NIL. Disclosure of Interests Saadia Sasha Ali: None declared, Naveen Ravichandran: None declared, Parikshit Sen: None declared, Jessica Day Grant/research support from: JD has received research funding from CSL Limited., Mrudula Joshi: None declared, Sreoshy Saha: None declared, Rohit Aggarwal Consultant of: RA has a consultancy relationship with and/or has received research funding from the following companies: Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, and Roivant., Grant/research support from: RA has a consultancy relationship with and/or has received research funding from the following companies: Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, and Roivant., Vikas Agarwal: None declared, Hector Chinoy Speakers bureau: Speaker for UCB, and Biogen. HC was supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme., Grant/research support from: Has received grant support from Eli Lilly and UCB, consulting fees from Novartis, Eli Lilly, Orphazyme, Astra Zeneca, Oliver Distler Speakers bureau: OD has consultancy relationships with and/or has received research funding from or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three years: Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur and UCB. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143)., Consultant of: OD has consultancy relationships with and/or has received research funding from or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three years: Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur and UCB. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143)., Grant/research support from: OD has consultancy relationships with and/or has received research funding from or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three years: Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur and UCB. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143)., Carlo Vinicio Caballero: None declared, Carlos Enrique Toro Gutierrez: None declared, Dey Dzifa: None declared, Ashima Makol: None declared, Ai Lyn Tan Speakers bureau: Has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB., Consultant of: has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB., Samuel Katsuyuki Shinjo: None declared, Vishwesh Agarwal: None declared, Latika Gupta: None declared.
  • Editor: London: BMJ Publishing Group LTD
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.